Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus
Executive Summary
The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might want to exit the primary care ADHD space.
You may also be interested in...
FDA's NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis, Rituxan Hycela, Haegarda
Original new drugs and biologics recently approved by US FDA.
Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)
Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues – but it won't launch the drug outside the US for some time.
Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.